Will Eli Lilly (LLY) Q2 Zepbound sales be above __?$4B
ResolvedOutcome: Yes$399as of
Odds now
This market has resolved Yes. Final market pricing put YES at 100%, as of .
YES100¢
NO0¢
as of
What moved the odds?
4 AI-matched news signals on this market, newest first. Entry price is the called side when the news hit; the signed return marks it against the final price as of .
Lilly once again beats expectations as tirzepatide accounts for 64% of revenue. • Eli Lilly posted $23 billion in second-quarter revenues, coming in about $3 billion above analysts' estimates. Lilly also once again raised its full-year revenue guidance to between $85 billion and $87 ...
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
*ELI LILLY 2Q ADJ EPS $8.38 VS. $6.31 Y/Y • *ELI LILLY 2Q REV. $22.97B, EST. $20.59B • *ELI LILLY 2Q ZEPBOUND REV. $4.93B, EST. $4.64B • • *ELI LILLY SEES FY REV. $85.0B TO $87.0B, SAW $82.0B TO $85.0B
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Where does the news lean?
4YES0NO0neutraltrailing 24h
Average match confidence across the listed signals: 93%.
How did this market resolve?
This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Related markets
See all outcomes for Will Eli Lilly (LLY) Q2 Zepbound sales be above __? — the full event, with combined odds and signal timeline.